Peptides for Thin Endometrium: Enhancing IVF Outcomes

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Thin endometrium poses a challenge in IVF. Growth Hormone (GH) and IGF-1 promote endometrial growth systemically, while Platelet-Rich Plasma (PRP) peptides offer localized regenerative and angiogenic effects. Both aim to improve endometrial thickness and receptivity, offering promising adjuncts to conventional treatments for better IVF outcomes.

Thin endometrium, typically defined as an endometrial thickness of less than 7 mm, is a significant challenge in reproductive medicine, often leading to recurrent implantation failure and infertility. A suboptimal endometrial lining can hinder embryo implantation and subsequent pregnancy progression. While conventional treatments include estrogen supplementation, a growing body of research is exploring the use of peptides to improve endometrial thickness and receptivity by targeting cellular proliferation, angiogenesis, and tissue remodeling.

Growth Hormone (GH) and IGF-1: Promoting Endometrial Growth

Growth Hormone (GH), a peptide hormone secreted by the pituitary gland, and its mediator, Insulin-like Growth Factor-1 (IGF-1), play crucial roles in cellular proliferation and tissue development. Receptors for GH are found on the human endometrium, suggesting a direct role in endometrial growth. In women with thin endometrium, GH supplementation has been shown to improve endometrial thickness (EMT) and potentially enhance pregnancy rates. For instance, a meta-analysis (Wang et al., 2024) highlighted GH's ability to improve EMT, likely by stimulating local IGF-1 production and promoting endometrial cell proliferation and differentiation.

Typical dosing for GH in IVF protocols for thin endometrium might involve 2-4 IU daily, administered subcutaneously, often initiated during the follicular phase. The goal is to enhance the proliferative phase of the endometrium, ensuring it reaches an adequate thickness and quality for embryo implantation. This approach directly addresses the underlying issue of insufficient endometrial growth, offering a physiological mechanism to improve uterine receptivity.

Platelet-Rich Plasma (PRP) Peptides: Regenerative and Angiogenic Effects

Platelet-Rich Plasma (PRP) is an autologous blood product containing a high concentration of platelets, which release numerous growth factors and peptides upon activation. These bioactive molecules, including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β), are crucial for tissue regeneration, angiogenesis, and anti-inflammatory processes. In the context of thin endometrium, PRP has shown promise in improving endometrial thickness and enhancing implantation rates.

Hysteroscopic injections of PRP into the endometrium have been reported to improve endometrial thickness in women with refractory thin endometrium (Chen et al., 2025). The mechanism involves the localized delivery of growth factors that stimulate endometrial cell proliferation, improve blood supply, and modulate the inflammatory environment, thereby fostering a more receptive uterine lining. While the exact peptide composition and optimal preparation of PRP can vary, the principle is to harness the body's natural healing capabilities. A typical PRP treatment might involve 0.5-1.0 ml of PRP injected into the uterine cavity or directly into the endometrium, often performed in the follicular phase.

GH/IGF-1 vs. PRP Peptides: Systemic Hormonal vs. Localized Regenerative

The distinction between Growth Hormone/IGF-1 and PRP peptides for thin endometrium lies in their mode of action and delivery. GH and IGF-1 represent a systemic hormonal approach, influencing endometrial growth through endocrine signaling. While GH is administered systemically, its effects on the endometrium are mediated by local IGF-1 production and direct receptor binding. This approach aims to boost the overall proliferative capacity of the endometrium.

In contrast, PRP peptides offer a localized regenerative approach, delivering a concentrated cocktail of growth factors directly to the uterine lining. This method focuses on stimulating local cellular repair, angiogenesis, and modulating the microenvironment without significant systemic hormonal effects. The nuance is that GH/IGF-1 provides a broad anabolic signal, while PRP offers a targeted regenerative stimulus. Both aim to improve endometrial thickness, but through different physiological pathways, making them potentially complementary in challenging cases of thin endometrium.

Clinical Takeaway

For women struggling with thin endometrium, peptide therapies offer promising avenues to improve uterine receptivity and IVF outcomes. Growth Hormone (e.g., 2-4 IU daily subcutaneously during the follicular phase) can enhance endometrial proliferation through systemic and local IGF-1 mediation. Platelet-Rich Plasma (PRP) peptides (e.g., 0.5-1.0 ml injected hysteroscopically) provide localized regenerative and angiogenic support, fostering a healthier uterine lining. While both approaches are still under active investigation, clinicians should consider these peptides as potential adjuncts to conventional estrogen therapy, particularly in refractory cases. The choice between or combination of these therapies should be individualized based on the patient's specific profile and response, with continued monitoring of endometrial thickness and receptivity markers. Further robust clinical trials are essential to establish definitive protocols and long-term efficacy.